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Abstract The mRNA of transferrin receptor (TfR) is constitu- 
tively expressed in proliferating human leukaemic HL-60 cells. 
Treatment of HL-60 cells with phorbol 12-myristate 13-acetate 
(PMA), a protein kinase C (PKC) activator, or dibutyryl-cyclic 
AMP (dbcAMP), a protein kinase A (PKA) activator, resulted 
in a 90% decrease in the level of TfR mRNA. Inhibition of TfR 
mRNA expression induced by 10 nM PMA and 100 /tM 
dbcAMP was abolished by prior incubation of cells with 0.1-1.0 
/tM GFI09203X, a PKC-specific inhibitor, and 1-10 pM H-89, 
a PKA-specific inhibitor, respectively. The blocking effects of 
GF109203X and H-89 were dose-dependent and complete at the 
highest concentrations of the inhibitors used. Although treatment 
of cells with GF109203X or H-89 alone did not alter the constitu- 
tive expression of TfR mRNA, incubation of cells with 30-100 
nM staurosporine, a wide-spectrum protein kinase inhibitor, re- 
suited in suppression of the constitutive xpression of TfR mRNA 
in a dose-dependent manner. These results suggest hat (i) the 
down-regulation of TfR mRNA expression during the differentia- 
tion of HL-60 cells can be mediated by activation of either PKC 
or PKA; (ii) the constitutive xpression of TfR mRNA in prolif- 
erating HL-60 cells is staurosporine-sensitive and is probably 
maintained by protein kinase(s) other than PKC and PKA. 
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1. Introduction 
The transferrin receptor (TfR), which is constitutively ex- 
pressed in the proliferating normal and malignant cells, has 
been considered as a proliferation marker in a number of cellu- 
lar systems [1,2]. Cessation of cell growth or terminal differen- 
tiation results in down-regulation f TfR expression [3]. The 
human promyelocytic leukaemia cell line HL-60 is a model for 
studying this aspect of cellular egulation as these cells can be 
induced to differentiate into either granulocytes by retinoic 
acids and dibutyrl-cyclic AMP (dbcAMP) or monocytes/mac- 
rophages by 1,25-dihydroxyvitamin D 3 and phorbol 12-myris- 
tate 13-acetate (PMA) [4~7]. Upon induction of differentiation 
by these agents, the expression of TfR mRNA and the protein 
were decreased [3,8,9]. Since PMA and dbcAMP are able to 
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modulate the expression of TfR, participation ofprotein kinase 
C (PKC) and protein kinase A (PKA) are implicated, although 
no direct evidence for this action has been demonstrated. In this 
study, we investigate he role of protein kinases in the regula- 
tion of TfR expression i  HL-60 cells by using GF109203X, a
PKC-specific inhibitor [10], H-89, a PKA-specific inhibitor [11 ], 
as well as staurosporine, a wide-spectrum protein kinase inhib- 
itor [12]. We demonstrate hat the down-regulation of TfR 
mRNA expression in HL-60 cells induced by PMA and 
dbcAMP was completely blocked by GF109203X and H-89, 
respectively. Although treatment of cells with GF109203X or 
H-89 alone did not alter the constitutive xpression of TfR 
mRNA, incubation of cells with staurosporine r sulted in sup- 
pression of the TfR mRNA level. These pharmacological evi- 
dences uggest that the down-regulation f TfR mRNA expres- 
sion during the differentiation f HL-60 cells can be mediated 
by activation of either PKC or PKA. On the other hand, the 
constitutive expression of TfR mRNA in proliferating HL-60 
cells is staurosporine-sensitive and is probably maintained by 
protein kinase(s) other than PKC and PKA. The effectiveness 
of these protein kinase inhibitors in elucidating the cellular 
mechanisms involved in cell growth and differentiation f HL- 
60 cells are also revealed. 
2. Materials and methods 
2.1. Chemicals, probes and cell culture 
GF109203X, H-89 and staurosporine were purchased from Calbio- 
chem (San Diego, CA). PMA and dbcAMP were from Sigma (St. Louis, 
MO). The cDNA probes for human TfR (pcDTR1), human actin 
(HHCI89) and HL-60 cell line were obtained from the American Type 
Culture Collection (Rockville, MD). HL-60 cells were maintained in
RPMI 1640 with 10% fetal calf serum. The TfR expression i creased 
significantly after they were subcultured [3]. To minimize this effect 
during the experiments, he cells were washed and cultured at 5 x 105 
cells/ml in the same medium with reduced serum (1%) for 24 h before 
the addition of drugs. Under this condition, DNA synthesis was main- 
tained and the TfR expression fthe control culture remained constant 
during the course of experiments. 
2.2. Northern blot analysis 
Total RNA was isolated according to the method of Chomczynski 
and Sacchi [13]. Equal amounts of samples (10/2g) were size-fraction- 
ated on 1% formaldehyde-agarose gel, transferred toHybond-N mem- 
brane (Amersham) and hybridized with labeled probes according to 
procedures ofSambrook and Maniatis [14]. 
2.3. FH]Thymidine incorporation 
At the last 4 h of incubation with drugs, the cells were pulsed labeled 
with l/2Ci [3H]thymidine (5 Ci/mmol). After that, the cells were washed 
with phosphate-buffered saline and lysed with 0.1% Triton X-100 be- 
fore incubated with 5% trichloroacetic a id. The acid-insoluble material 
was collected on glass fiber filter and measured by liquid scintillation 
counting. 
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Fig. 1. Effects of PMA and dbcAMP on TfR mRNA expression i  
HL-60 cells. Cells were treated with indicated concentrations ofPMA 
(A) or dbcAMP (B) for 24 h. The TfR mRNA level was determined by 
Northern blot hybridization. 
3. Results 
As shown in Fig. 1, the mRNA of TfR was constitutively 
expressed in the proliferating HL-60 cells. Treatment of these 
cells with PMA, a PKC activator, or dbcAMP, a PKA activa- 
tor, for 24 h resulted in a 90% decrease in TfR mRNA level. 
The concentrations of these two activators required to inhibit 
half-maximally TfR mRNA expression (ICs0) were about 10 
nM and 100 ¢tM, respectively. By contrast, treatment of cells 
with 1 HM GF109203X, a PKC-specific inhibitor, or 10/IM 
H-89, a PKA-specific inhibitor, did not modulate the expres- 
sion ofTfR mRNA (Fig. 2A,B). Nevertheless, inhibition of TfR 
mRNA expression induced by PMA (10 nM) could be abol- 
ished by preincubating the cells with GF109203X (0.1-1.0 ¢tM) 
(Fig. 2A). As a negative control, this PKC inhibitor at the 
previous concentrations u ed was ineffective in nullifying the 
inhibitory action of dbcAMP (100/tM) (Fig. 2A). Similarly, 
prior addition of H-89 (1-10/IM) to the cells abrogated the 
effect ofdbcAMP (100/tM) but not that of PMA (10 nM) (Fig. 
2B). At the highest concentrations u ed, both GF109203X and 
H-89 fully inhibited the action of PMA and dbcAMP on TfR 
mRNA expression, respectively. 
The effect of these protein kinase modulators on DNA syn- 
thesis was also investigated. [3H]Thymidine incorporation was 
markedly suppressed by PMA (10 nM) or dbcAMP (100 ¢tM) 
but not affected by GF109203X (1 pM) or H-89 (10 pM). 
However, preincubation of cells with GF109203X or H-89 re- 
versed the inhibitory action of PMA and dbcAMP, respectively 
(Table 1). 
The effect of staurosporine, a wide-spectrum protein kinase 
inhibitor, on TfR mRNA expression was also tested. At con- 
centrations that are commonly used for the inhibition of pro- 
tein kinases (1-100 nM), staurosporine did not mimic the effect 
of GF109203X on PMA-treated cells or H-89 on dbcAMP- 
treated cells (not shown). However, incubation of cells with 
30 100 nM of staurosporine alone resulted in a suppression of 
mRNA level of TfR in a dose-dependent manner. At the high- 
est concentration of staurosporine used, more than 90% of the 
TfR mRNA expression was inhibited (Fig. 3). Also, within this 
range of concentrations of staurosporine, DNA synthesis, but 
not cell survival, was inhibited (data not shown). 
4. Discussion 
GF109203X and H-89 are novel and specific inhibitors for 
PKC and PKA, respectively. In this study, we show that 
GF109203X and H-89 completely blocked the down-regulation 
of TfR mRNA expression i  HL-60 cells induced by PMA and 
dbcAMP, respectively. These results suggest hat activation of 
either PKC or PKA may be necessary or perhaps ufficient o 
induce down-regulation f TfR gene expression i  HL-60 cells. 
It should be noted that PMA-modulated responses have been 
attributed to either activation or down-regulation f PKC (loss 
of the protein kinase activities through proteolysis upon pro- 
longed treatment of PMA) [I 5-20]. The present results indicate 
that the down-regulation f TfR mRNA expression is unlikely 
mediated by the depletion of PKC activities upon prolonged 
treatment of PMA, otherwise GF109203X would not have re- 
versed the inhibitory effect of PMA. As for cAMP-modulated 
responses, although many experimental evidences have indi- 
cated that PKA activation was required, certain studies have 
implicated that PKA-independent mechanisms may also play 
a role in some cases ([21] and references therein). Our experi- 
ments using H-89 as a PKA-specific inhibitor demonstrate hat 
the effect of dbcAMP on TfR mRNA expression is PKA- 
dependent. 
The effects of PMA and dbcAMP on the down-regulation f 
TfR gene expression i leukaemic cells were shown to be medi- 
ated at transcription level [9,22]. It is noteworthy that the pro- 
moter sequence of the TfR gene contains a TRE/CRE-like 
element as revealed by sequence homology and DNAase foot- 
printing [23]. Conceptually, this element is recognized by tran- 
scription factor(s) AP-l(Jun) and/or CREB which are activated 
by PKC and/or PKA [24]. In fact, we have demonstrated that 
an increase in AP-1 binding to the TRE/CRE-like element was 
associated with the down-regulation f TfR expression during 
HL-60 cell differentiation i duced by PMA [25]. Consistent to 
PKC-/AP- 1-modulated gene expression model, this binding ac- 
tivity could be abolished by preincubation of the cells with 
GF109203X (data not shown). 
The constitutive expression of transferrin receptor is associ- 
ated with active DNA synthesis in proliferating HL-60 cells. 
Our results indicate that both GF109203X and H-89 did not 
affect he constitutive expression of TfR mRNA and also DNA 
Table 1 
Effects of GF109203X and H-89 on the PMA- and dbcAMP-induced 
inhibition of DNA synthesis 
Treatment [3H]Thymidine 
incorporation 
(% Control + S.D., n = 3) 
PMA (10 nM) 8 + 1 
GF109203X (1/zM) 96 + 6 
GF109203X (1 pM) + PMA (10 nM) 77 + 15 
dbcAMP (100 pM) 38 + 5 
H-89 (10pM) 81 + 19 
H-89 (10/zM) + dbcAMP (100 ,uM) 78 + 15 
Cells were treated with the indicated agents for 24 h. DNA synthesis 
was determined by [3H]thymidine incorporation. The mean incorpo- 
rated count of the control culture was 2400 cpm/106 cells. 
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Fig. 2. Effects of GF109203X and H-89 on the PMA- and dbcAMP-induced down-regulation fTfR mRNA expression i HL-60 cells. Cells were 
preincubated with indicated concentrations of GF109203X (A) or H-89 (B) for 30 min and PMA (10 nM) or dbcAMP (100 pMI was then added 
for 24 h. The TfR mRNA level was determined by Northern blot hybridization. 
synthesis even at high concentrations (at least 70 times of the 
in vitro ICs0 for PKC [10] or PKA [11]). Thus, it is unlikely that 
the proliferation-associated processes of HL-60 cells are main- 
tained by the basal activity of PKC and PKA. This also indi- 
rectly reveals that in contrast to other protein kinase inhibitors 
which inhibit cell growth or even induce cell death of HL-60 
ceils at concentrations u ed for inhibition of protein kinases 
[26,27], GFI09203X and H-89 are relatively non-cytotoxic and 
presumably more specific in protein kinase inhibition. 
Staurosporine is a potent inhibitor of PKC. However stauro- 
sporine also inhibits a wide spectrum of protein kinases ([27] 
and references therein). It can inhibit both PKC and PKA with 
close in vitro 1C50 (3 and 15 nM, respectively) [12,28]. Contrary 
to our expectation, this inhibitor, used within the range of 
concentrations which could inhibit PKC and PKA, did not 
block the down-regulation f TfR mRNA expression i duced 
by PMA or dbcAMP [28]. The study from Matsui and associ- 
ates shows that H-7, a serine/threonine protein kinase inhibitor, 
caused only subtle reversal on the suppressive effect of PMA 
on TfR expression [29]. The reasons for these observations are 
still unclear. The possibility exists that these inhibitors may act 
on protein kinases or other cellular machinery which are re- 
sponsible for the constitutive expression of TfR. In fact, we 
found that the constitutive expression of TfR mRNA was sup- 
pressed by staurosporine. It is possible that the expression of 
TfR mRNA in proliferating cells is maintained by certain pro- 
tein kinases (other than PKC and PKA) that are inhibited by 
staurosporine. Of course, we cannot rule out that the effect of 
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Fig. 3. Effect of staurosporine on the constitutive expression of TfR 
mRNA in HL-60 cells. Ceils were treated with indicated concentrations 
of staurosporine for 24 h. The TfR mRNA level was determined by 
Northern blot hybridization. 
staurosporine on TfR expression may be due to non-specific 
perturbation other than the inhibition of protein kinases. Nev- 
ertheless, this result demonstrates that staurosporine may be an 
useful pharmacological tool for studying the constitutive x- 
pression of TfR or other proliferation-associated processes in 
HL-60 cells. 
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